ArticleDrug delivery and translational research2026
A liposomal formulation of cyclosporine a shows promising results in treating symptoms of moderate to severe dry eye disease in dogs.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The prevalence of dry eye disease (DED) is rising globally, increasingly affecting young adults. Although artificial tears are commonly used, unfortunately they do not address the inflammatory component of the disease. For this reason, in patients whose symptoms persist despite the use of artificial tears, anti-inflammatory agents such as the immunosuppressant cyclosporine A (CyA) are clinically indicated to reduce the underlying inflammation in DED. In this study, a CyA-loaded liposomal formulations composed of analogous components to the lipid and aqueous layers of the natural tears (CyA-lipo) and dispersed in an aqueous solution of sodium hyaluronate (CyA-lipo-NaHa) has been developed. Formulations were analysed for physicochemical properties, and in vitro tolerance using human corneal and conjunctival cell lines over a short-term stability study at 25 °C and 2–8 °C. In vivo tolerance was assessed in rabbits, and therapeutic efficacy was evaluated in dogs diagnosed with DED. Average vesicles’ size resulted in 204.2 ± 4.3 nm and 198.7 ± 6.0 nm for CyA-lipo and CyA-lipo-NaHa respectively. Both formulations rendered osmolarity values close to 200 mOsm and surface tension values below 31 mN/m. The addition of sodium hyaluronate produced an increase of viscosity with values of 6.030 ± 0.316 mPa·s for CyA-lipo-NaHa and 0.950 ± 0.073mPa·s for CyA-lipo. Cell viability was above 80% in corneal and conjunctival cells, and no signs of ocular surface damage in rabbit were observed. In dogs, ocular surface parameters, Schirmer’s test values in particular, improved significantly after two months of treatment (< 13 mm/min before and higher than15 mm/min in all animals after treatment). This liposomal formulation demonstrates optimal physicochemical properties, biocompatibility, and therapeutic efficacy, supporting its potential as an optimised treatment for DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.